Results of a long-term, federally funded study of cognitively healthy adults — most with a family history of Alzheimer’s disease — have added to evidence that low spinal fluid levels of a protein linked to learning and memory in mice may serve as an early predictor of mild cognitive impairment (MCI) years before symptoms appear.
A new study by scientists at the Jean Mayer USDA Human Nutrition Research Center on Aging (HNRCA) at Tufts University suggests that a micronutrient in human breast milk provides significant benefit to the developing brains of newborns, a finding that further illuminates the link between nutrition and brain health and could help improve infant formulas used in circumstances when breastfeeding isn’t possible.
New Alzheimer’s research from UVA Health suggests that enhanced light sensitivity may contribute to “sundowning” – the worsening of symptoms late in the day – and spur sleep disruptions thought to contribute to the disease’s progression.
New research shows the importance of long-term commitment to the MIND diet for reaping the greatest benefit to brain health.
New therapies for early Alzheimer’s disease, monoclonal antibodies that remove amyloid-β plaques in the brain, are bringing hope to people whose lives have been affected by the disease. To help neurologists discuss these therapies with patients and caregivers, the American Academy of Neurology has developed an Emerging Issues in Neurology article, published online on July 26, 2023, in Neurology®, the medical journal of the American Academy of Neurology.
People who carry the gene variant associated with the strongest risk for Alzheimer’s disease may lose their ability to detect odors earlier than people who do not carry the gene variant, which may be an early sign of future memory and thinking problems, according to a study published in the July 26, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology. The gene variant associated with this increased risk of Alzheimer’s is called APOE e4.
Constant Therapy Health, a next generation digital health company, today announced that the organization is empowering Boston University Center for Brain Recovery and The University of Texas at Austin neuroscientists, data engineers and computational scientists with the AI-driven, real-world data needed to bring precision medicine to post-stroke speech, language and cognitive rehabilitation.
Kundalini yoga, a form of yoga that focuses on breathing, meditation, and mental visualization, appeared beneficial for older women who had risk factors for Alzheimer’s disease and concerns about episodes of memory decline, according to a UCLA Health study.
A recent study has used Artificial Intelligence (AI) to reveal the remarkable potential of extra virgin olive oil (EVOO) in the fight against Alzheimer's disease (AD). Researchers combined AI technology, chemistry, and omics research to identify specific bioactive compounds in EVOO that show promising effects in treating and preventing AD.
A new study by researchers at Case Western Reserve University revealed that the progression of Alzheimer's disease (AD) can be slowed by suppressing a specific protein in the brain that causes corrosion.
More than 1.4 million times a year, people with Alzheimer’s disease and other forms of dementia end up in emergency care, making up nearly 7% of all emergency visits for any reason by people over age 65, a new study shows. Compared with their peers who don’t have dementia, these patients have twice the rate of seeking emergency care after an accident or a behavioral or mental health crisis.
A new study suggests that incorporating olive oil into your diet could help reduce the risk of dying from dementia.
Research results, published July 17 in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, show the first-ever county-level estimates of people living with Alzheimer’s disease in all U.S. counties.
The secret to protecting your memory may be a staple of a bodybuilder’s diet. RUSH researchers recently discovered that a muscle-building supplement called beta-hydroxy beta-methylbutyrate, also called HMB, may help protect memory, reduce plaques and ultimately help prevent the progression of Alzheimer’s disease.
The latest research in psychology and psychiatry on Newswise.
Volunteering in late life is associated with better cognitive function — specifically, better executive function and episodic memory, according to a new UC Davis study.
Using data from diverse populations around the world, researchers have developed an algorithm to help predict the risk of developing Alzheimer’s disease based on genetic information in patients with a wide variety of ethnic backgrounds. While additional ethnicities should be included in future studies, this work aims to eliminate disparities in diagnosis of the disease.
The majority of older adults with cognitive impairment are still driving, despite concerns raised by caregivers and others, a study finds. Researchers say it’s best for caregivers to start conversations surrounding driving earlier while the care recipient is able to understand and actively participate in the discussion.
Parkinson's disease, another neurodegenerative process, produces in patients a unique smell, which trained dogs can detect. Alzheimer's disease, the leading dementia, needs to be similarly studied. This $200,000 challenge award is posted to help stimulate this necessary research.
The first study in the world to compare cholesterol-lowering medications on a range of diseases has good and bad news for more than 200 million people.
It's fragile X awareness month, and the NIH has renewed funding for a key study of the neurodegenerative condition fragile X-associated tremor ataxia syndrome (FXTAS).
A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 13, entitled, “Cognitive rescue in aging through prior training in rats.”
Higher levels of vitamin B-related amino acids may be linked to the risk of dementia associated with a certain type of air pollutants called particulate matter, according to a study published in the July 19, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology. The study does not prove that pollution or amino acids cause dementia, but it suggests a possible link among them.
Eighty percent of older adults see the benefit of tests that can give an early warning that a person’s memory and thinking abilities have started to decline, a new poll of people age 65 to 80 finds. And 60% think that health care providers should offer cognitive screening to all older adults every year
20240326113011.png&width=400&height=400){kind=logo}
Coffee might do more than just wake you up. Research now published in ACS’ Journal of Agricultural and Food Chemistry shows that, in preliminary in vitro laboratory tests, espresso compounds can inhibit tau protein aggregation — a process that is believed to be involved in Alzheimer’s disease.
Lewy body disease is the second most common neurodegenerative disease after Alzheimer's disease. A research group from Lund University has now shown that the disease can be detected before symptoms appear, using a spinal fluid test.
The Lasker Foundation announced today that Salman E. Qasim, PhD, a postdoctoral fellow at the Icahn School of Medicine at Mount Sinai, is among five winners of its 10th annual Lasker Essay Contest.
Researchers from Indiana University School of Medicine had a large presence and leadership role at the 2023 Alzheimer's Association International Conference in Amsterdam, Netherlands, with involvement in more than 150 presentations at the four-day meeting. The annual conference is the largest and most influential international meeting dedicated to advancing dementia science.
As the primary medical specialty that provides care to people with Alzheimer’s disease, the American Academy of Neurology has been invited to testify on Capitol Hill before members of the United States House of Representatives on new drugs for Alzheimer’s disease.
Pitt received $1 million to support four projects that advance new and ongoing translational research on aging. These studies have the potential to create novel products and technologies to improve health outcomes and reduce the burden of age-related problems.
A recent study from the lab of the University of Kentucky’s Sanders-Brown Center on Aging Director Linda Van Eldik, Ph.D., has been published in PLOS ONE. The work centers around the idea that various anti-inflammatory drugs could be effective treatments for Alzheimer’s disease (AD). This study focused on a protein known as p38.
Press materials are now available for NUTRITION 2023, the annual flagship meeting of the American Society for Nutrition (ASN).
The neurons in our bodies are dotted with tiny pores that let essential molecules pass in and out of our cells. Neurons need these channels to send the signals that allow us to move, think, and perceive the world around us. Now, structural biologists at Cold Spring Harbor Laboratory (CSHL) have captured never-before-seen images of one of the largest pores in human neurons.
Study represents a major milestone toward health equity for underrepresented populations in Alzheimer’s disease research
Researchers at Washington University School of Medicine in St. Louis and Lund University in Sweden have discovered an Alzheimer's biomarker in the cerebrospinal fluid known as MTBR-tau243 can be used to track the progression of disease and could speed drug development.
Because amyloidosis doesn’t affect a specific organ and can be present throughout the body including the heart, kidneys, liver and brain, unraveling the underlying cause of amyloid fibril creation – a hallmark of this disease – is complex and challenging. A monumental $11.5 million gift from philanthropists Ann and John Wood will enable FAU’s Schmidt College of Medicine to create a game-changing infrastructure using a whole-body approach and multi-disciplinary team.
Older people who have little social contact with others may be more likely to have loss of overall brain volume, and in areas of the brain affected by dementia, than people with more frequent social contact, according to a study published in the July 12, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology.
That experiences leave their trace in the connectivity of the brain has been known for a while, but a pioneering study by researchers at DZNE and TUD Dresden University of Technology now shows how massive these effects really are.
The molecular processes responsible for natural ageing of cells are poorly understood. Studying conditions in humans where ageing is accelerated due to genetic causes presents opportunities to learn about the mechanisms that control ageing and devise strategies to slow down the ageing process.
What makes the vital layer of protective cells around the brain and spinal cord — the blood-brain barrier — more or less permeable has been one of the more mystifying questions in neuroscience.
A simple but revolutionary test to improve early detection for dementia and Alzheimer’s disease could soon be helping patients and their families, thanks to a significant £1.5 million funding boost awarded to the universities of Bath and Bristol.
On July 6, 2023, the U.S. Food and Drug Administration (FDA) granted full approval to lecanemab, marketed as Leqembi, for the treatment of Alzheimer’s disease. The University of Kentucky’s Sanders-Brown Center on Aging has been working with this drug and others like it for more than a decade.
A $40.5 million grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), will fund the Asian Cohort for Alzheimer’s Disease (ACAD) study at Penn Medicine and 15 other academic research centers across the United States and Canada.
Age-related cognitive decline and the escalating prevalence of Alzheimer’s disease are pressing social challenges as the population of those 65 and older continues to expand. Age is the primary risk factor, but research has shown that social and structural determinants of health play significant roles in the higher incidence of Alzheimer’s among marginalized communities.
Hackensack Meridian Health Physicians react to FDA approval of Alzheimer's drug lecanemab/ Leqembi. Available to discuss its uses, side effects and instances when they have prescribed it.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
